We are living in an era of transformation for oncology research and treatment. The realization of immunotherapy via various modalities, chemo-free options, early-stage treatment and detection—not to mention the genomic revolution—are bringing many new options to patients across a wider span of diseases. These advancements challenge the status quo approach manufacturers have historically taken to commercialize, compete and shape the market.
During this webinar, you will gain a greater appreciation for:
- The macro evolution of oncology pipeline development and recent emerging pharma launches, with a major emphasis on precision medicine
- The impact of new treatment paradigms, detection techniques and the commitment to achieving health equity across various stakeholders in the oncology ecosystem
- The environmental changes across the patient care continuum, including technology advancements (AI, digital) and manufacturer portfolios that are creating a case for change in commercialization